Fortitude Family Office’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Fortitude Family Office’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.27K	Buy	41 +1	+3%	+$27	﹤0.01%	2160
2026 Q2	$728	Hold	40	–	–	﹤0.01%	1867
2026 Q1	$821	Buy	+40	New	+$8.03K	﹤0.01%	1559

Fortitude Family Office's IRLA Position: Q3 2026 in Review

Fortitude Family Office increased its IRulya Therapeutics Inc. Common Stock (IRLA) stake by 2.5% in Q3 2026, buying an estimated $27 and bringing the position to 41 shares worth $1.27K. The position accounts for ﹤0.01% of the portfolio, ranked #2160.

Fortitude Family Office first reported a position in IRLA in Q1 2026 and has held it in 3 quarters since. 1 fund tracked by Wall St. Rank holds IRLA as of Q3 2026.

Fortitude Family Office held 41 shares of IRulya Therapeutics Inc. Common Stock worth $1.27K as of Q3 2026.
Fortitude Family Office bought 1 IRulya Therapeutics Inc. Common Stock share in Q3 2026, an estimated $27.
IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2160 holding.
Fortitude Family Office first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2026 and has held it in 3 quarters since.
1 fund tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.